Inhibition of melanocyte death

Inhibition of melanocyte death refers to a therapeutic strategy aimed at halting the progression of vitiligo and other depigmenting disorders by preventing the destruction of pigment-producing melanocytes [1, 5]. This biological process is primarily driven by an autoimmune attack involving CD8+ T cells, which utilize the interferon-gamma (IFN-gamma)/Janus kinase (JAK)/STAT1 signaling pathway to induce melanocyte apoptosis and senescence [5, 7]. Additionally, intrinsic oxidative stress and the accumulation of reactive oxygen species (ROS) contribute to cell death by activating pro-apoptotic pathways such as p38 MAPK and JNK [2, 4]. Pharmacological strategies to inhibit this death process include the use of JAK inhibitors to block immune-mediated destruction, and antioxidants or polyphenols to stabilize the melanocyte microenvironment against oxidative damage [1, 3, 7]. By preserving the existing melanocyte population, these interventions allow for the stabilization of skin pigmentation and facilitate repigmentation from existing follicular reservoirs [8, 11].

Other names

Melanocyte preservationPrevention of melanocyte apoptosisMelanocyte protectionMelanocyte survival pathway

Blockade of the IFN-gamma/JAK/STAT signaling axis to prevent T-cell recruitment, activation of the NRF2 antioxidant pathway to neutralize reactive oxygen species, and stimulation of the MC1R/cAMP survival pathway to promote cellular proliferation and resilience.